A randomized, double-blind, placebo-controlled phase 2 study of an oral p38α MAPK inhibitor, SCIO-469, in patients with active rheumatoid arthritis

被引：0
|
作者：
Genovese, M. C. [1 ]
Cohen, S. B. [2 ]
Wofsy, D. [3 ]
Weinblatt, M. E. [4 ]
Firestein, G. S. [5 ]
Brahn, E. [6 ]
Strand, V. [7 ]
Baker, D. G. [8 ]
Tong, S. E. [9 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Metroplex Clin Res Ctr, Dallas, TX USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Univ Calif San Diego, San Diego, CA 92103 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Stanford Univ, Portola Valley, CA USA
[8] Centocor Inc, Malvern, PA 19355 USA
[9] Scios J&J PRD, Mountain View, CA USA
来源：
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S431 / S432
页数：2
相关论文
共 50 条
  • [1] A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis
    Genovese, Mark C.
    Cohen, Stanley B.
    Wofsy, David
    Weinblatt, Michael E.
    Firestein, Gary S.
    Brahn, Ernest
    Strand, Vibeke
    Baker, Daniel G.
    Tong, Sandra E.
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (05) : 846 - 854
  • [2] Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
    Sokol, L.
    Cripe, L.
    Kantarjian, H.
    Sekeres, M. A.
    Parmar, S.
    Greenberg, P.
    Goldberg, S. L.
    Bhushan, V.
    Shammo, J.
    Hohl, R.
    Verma, A.
    Garcia-Manero, G.
    Li, Y-P
    Lowe, A.
    Zhu, J.
    List, A. F.
    LEUKEMIA, 2013, 27 (04) : 977 - 980
  • [3] Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
    L Sokol
    L Cripe
    H Kantarjian
    M A Sekeres
    S Parmar
    P Greenberg
    S L Goldberg
    V Bhushan
    J Shammo
    R Hohl
    A Verma
    G Garcia-Manero
    Y-P Li
    A Lowe
    J Zhu
    A F List
    Leukemia, 2013, 27 : 977 - 980
  • [4] Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study
    Blanco, Francisco J.
    Moericke, Ruediger
    Dokoupilova, Eva
    Codding, Christine
    Neal, Jeffrey
    Andersson, Mats
    Rohrer, Susanne
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (06) : 1144 - 1153
  • [5] Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
    Zou, Hejian
    Wan, Weiguo
    Xue, Yu
    Sun, Lingyun
    Zhang, Ning
    Chen, Haiying
    Shi, Xiaofei
    Liu, Shengyun
    Chen, Lin
    Ma, Xinmei
    Wei, Hua
    Jiang, Zhenyu
    Li, Xiaomei
    Fan, Hongtao
    Li, Hongbin
    Li, Jingyang
    Wu, Rui
    Shi, Guixiu
    Zhu, Jing
    Kong, Xiaodan
    Lu, Yuewu
    Cui, Xiaojing
    Zheng, Qianning
    Bai, Xiaoyan
    Dong, Guangchao
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5240 - 5242
  • [6] Efficacy, Pharmacodynamics, and Safety of VX-702, a Novel p38 MAPK Inhibitor, in Rheumatoid Arthritis Results of Two Randomized, Double-Blind, Placebo-Controlled Clinical Studies
    Damjanov, Nemanja
    Kauffman, Robert S.
    Spencer-Green, George T.
    ARTHRITIS AND RHEUMATISM, 2009, 60 (05): : 1232 - 1241
  • [7] A double-blind placebo-controlled randomized trial of oral saffron in the treatment of rheumatoid arthritis
    Sahebari, Maryam
    Heidari, Hossein
    Nabavi, Shima
    Khodashahi, Mandana
    Rezaieyazdi, Zahra
    Dadgarmoghaddam, Maliheh
    Hosseinzaheh, Hossein
    Abbasi, Shaghayegh
    Hashemzadeh, Kamila
    AVICENNA JOURNAL OF PHYTOMEDICINE, 2021, 11 (04) : 332 - 342
  • [8] Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study
    Ogrendik, Mesut
    RHEUMATOLOGY INTERNATIONAL, 2006, 26 (12) : 1132 - 1137
  • [9] Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study
    Mesut Ogrendik
    Rheumatology International, 2006, 26 : 1132 - 1137
  • [10] A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis
    Aranow, Cynthia
    Cush, John
    Bolster, Marcy B.
    Striebich, Christopher C.
    Dall'era, Maria
    Mackay, Meggan
    Olech, Ewa
    Frech, Tracy
    Box, Jane
    Keating, Richard
    Wasko, Mary Chester
    St Clair, William
    Kivitz, Alan
    Huang, Weiquang
    Ricketts, PetaGay
    Welch, Beverly
    Callahan, Sherrie
    Spychala, Meagan
    Boyle, Karen
    York, Kate
    Keyes-Elstein, Lynette
    Goldmuntz, Ellen
    Diamond, Betty
    Davidson, Anne
    RHEUMATOLOGY, 2020, 59 (07) : 1505 - 1513
12345